Jeffrey Madden

Jeffrey Madden has extensive work experience in various roles and industries. Jeffrey is currently serving as the Chief Executive Officer at ADvantage Therapeutics Inc., a company specializing in the development of therapies for neurodegenerative conditions, with a focus on Alzheimer's disease. In this role, they are responsible for overseeing the development and clinical trials of the company's lead compound, AD04, which is aimed at reducing AD pathology by stimulating and regulating the immune system. Prior to this, Jeffrey was a Partner and Portfolio Manager at IronBridge - A Division of RMB Asset Management for over 20 years. Jeffrey also worked as a Consultant at Accenture from 1998 to 2000.

Jeffrey Madden attended The University of Iowa Tippie College of Business from 1994 to 1998. Jeffrey obtained a Bachelor of Applied Arts (B.A.A.) degree with a focus on Finance, Business Honors and Distinction.